tetano
Editor, Senior Moderator
Vaccine X
. 2022 Aug;11:100165.
doi: 10.1016/j.jvacx.2022.100165. Epub 2022 May 2.
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
José L Casado[SUP] 1 [/SUP], Pilar Vizcarra[SUP] 1 [/SUP], Johannes Haemmerle[SUP] 2 [/SUP], Héctor Velasco[SUP] 3 [/SUP], Adrián Martín-Hondarza[SUP] 3 [/SUP], Mario J Rodríguez-Domínguez[SUP] 4 [/SUP], Tamara Velasco[SUP] 1 [/SUP], Sara Martín[SUP] 1 [/SUP], Beatriz Romero-Hernández[SUP] 4 [/SUP], Marina Fernández-Escribano[SUP] 2 [/SUP], Alejandro Vallejo[SUP] 1 3 [/SUP]
Affiliations
Abstract
Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4[SUP]+[/SUP] T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.
Keywords: AU, arbitrary units; CLIA, chemoluminiscent immunoassay; COVID-19, Coronavirus disease 2019; Cellular response; IgG, immunoglobulin G; Pre-existing immunity; RT-PCR, retrotranscriptasepolymerase chain reaction; S protein, Spike protein; SARS-CoV-2 humoral response; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; mRNA vaccine.
. 2022 Aug;11:100165.
doi: 10.1016/j.jvacx.2022.100165. Epub 2022 May 2.
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
José L Casado[SUP] 1 [/SUP], Pilar Vizcarra[SUP] 1 [/SUP], Johannes Haemmerle[SUP] 2 [/SUP], Héctor Velasco[SUP] 3 [/SUP], Adrián Martín-Hondarza[SUP] 3 [/SUP], Mario J Rodríguez-Domínguez[SUP] 4 [/SUP], Tamara Velasco[SUP] 1 [/SUP], Sara Martín[SUP] 1 [/SUP], Beatriz Romero-Hernández[SUP] 4 [/SUP], Marina Fernández-Escribano[SUP] 2 [/SUP], Alejandro Vallejo[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35529539
- PMCID: PMC9057925
- DOI: 10.1016/j.jvacx.2022.100165
Abstract
Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4[SUP]+[/SUP] T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.
Keywords: AU, arbitrary units; CLIA, chemoluminiscent immunoassay; COVID-19, Coronavirus disease 2019; Cellular response; IgG, immunoglobulin G; Pre-existing immunity; RT-PCR, retrotranscriptasepolymerase chain reaction; S protein, Spike protein; SARS-CoV-2 humoral response; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; mRNA vaccine.